Shahre Bours- Zagros Darou Parsian, a leading pharmaceutical and agricultural inputs company, has recorded an impressive performance in its financial statements for the fiscal year ending March 20, 2025, as published on the Codal platform.

Robust Revenue and Profit Growth

The financial report highlights a remarkable surge across all profitability metrics. The company’s operating revenue reached 2,596 billion tomans in 1403, reflecting a 59% increase compared to the previous year. This growth underscores the company’s successful expansion of operations and strengthened market presence for its pharmaceutical and agricultural products.

Gross profit soared to 1,583 billion tomans, marking a striking 97% rise from the prior year. Similarly, operating profit climbed to 1,449 billion tomans, up 92% from the previous year, demonstrating sustained operational efficiency and cost management.

Exceptional Net Profit and Shareholder Value

Net profit from continuing operations exceeded 1,000 billion tomans, achieving a 106% year-on-year increase, signaling a consistent and reliable profitability trend. The company’s total net profit also reached 1,004 billion tomans, reflecting a 106% growth compared to the previous year. This robust performance highlights Zagros Darou Parsian’s ability to convert revenue into substantial profits.

A standout metric from the report is the basic earnings per share, which reached 591 tomans in 1403, a 106% increase from the prior year. This significant rise reflects the company’s ability to create substantial value for shareholders, boosting investor confidence.

Strategic Implications for 1403 and Beyond

The exceptional financial results position Zagros Darou Parsian as a key player in Iran’s pharmaceutical and agricultural sectors. The company’s ability to achieve such growth amidst economic challenges highlights its strategic focus on operational excellence and market expansion.